MONDAY 21\textsuperscript{TH} NOVEMBER, 2016

09:00-09:15 Welcome: \textit{Maura Massimino & Veronica Biassoni & Lorenza Gandola}, Milano, Italy

09:15-12:15 Update on the SIOPE DIPG Registry and planned projects (e.g. “biopsy” module): \textit{Dannis van Vuurden}, Amsterdam, Holland/\textit{Carin Damen-Korbijn}, Den Haag, Holland

Update on DIPG reirradiation (Discussion of a reirradiation module within the SIOP DIPG Registry? Trial suggestions?): \textit{Geert Janssens}, Utrecht, Holland

Update on DIPG Longterm Survivor Study: \textit{Sophie Veldhuijzen-van Zanten}, Amsterdam/\textit{Christof Kramm}, Goettingen, Germany

12:15-13:00 Lunch

13:15-16:15 Ongoing and planned DIPG trials and investigations

Treatment of DIPG and pedHGG in Mexico: \textit{Enrique Lopez}, Mexico City, Mexico

A mutation-specific vaccination approach for H3.3K27M mutated gliomas: \textit{Katharina Ochs}, Heidelberg, Germany

Update on the planned DC vaccination trial in DIPG patients using primary DIPG cell lines: \textit{Andres Morales}, Barcelona, Spain

A multicenter evaluation of nimotuzumab containing regimens for pediatric diffuse intrinsic pontine gliomas: \textit{Rejin Kebudi}, Istanbul, Turkey

Update on the Milan sequential multi-reirradiation trial for newly diagnosed DIPG: \textit{Veronica Biassoni, Maura Massimino, Lorenza Gandola}, Milano
Histone 3.3/3.1 K27M mutations in non-brainstem diffuse midline gliomas: What do they really imply for survival? Michael Karremann, Mannheim, Germany

Novel Aspects of pedHGG/DIPG Molecular Diagnostics: Dominik Sturm, Heidelberg

16:15-16:30 Coffee break

16:30-19:30 Preclinical models and studies

Systemic AAV9-IFNβ gene therapy for glioma - Implications for DIPG: Miguel Sena-Esteves, Worcester, MA, USA

Preclinical models for DIPG: Esther Hulleman, Amsterdam, Natacha Entz-Werle/Anne-Florence Blandin, Strasbourg, France

Epigenetic treatment strategies for DIPG: Maria Wiese, Goettingen

20:00 Dinner Location to be announced

TUESDAY 22ND NOVEMBER, 2016

09:00-09:45 Can we open a SIOPE-Infant HGG Registry? André von Bueren, Geneva, Switzerland

09:45-11:15 Update on current and planned clinical trials and investigations in pedHGG

RAPIRI I et al.: Natacha Entz-Werle

HIT-HGG-Rez-Immunovac: Matthias Eyrich, Wuerzburg, Germany

(HIT-HGG-2007 & HIT-HGG-2013: Christof Kramm)

Longterm survivors in non-pontine pedHGG: Christof Kramm, Dannis van Vuurden

11:15-12:45 Update on projects in gliomatosis cerebri (e.g. International GC Registry)

Andres Morales; further presenters to be announced

12:45-13:30 Lunch

13:30-14:00 AOB and Farewell